Advertisement
Canada markets close in 3 minutes

  • S&P/TSX

    21,968.94
    +83.56 (+0.38%)
     

  • S&P 500

    5,099.97
    +51.55 (+1.02%)
     

  • DOW

    38,239.69
    +153.89 (+0.40%)
     

  • CAD/USD

    0.7318
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    83.65
    +0.08 (+0.10%)
     

  • Bitcoin CAD

    87,272.34
    -1,032.99 (-1.17%)
     

  • CMC Crypto 200

    1,330.24
    -66.30 (-4.57%)
     

  • GOLD FUTURES

    2,350.40
    +7.90 (+0.34%)
     

  • RUSSELL 2000

    2,001.65
    +20.53 (+1.04%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,926.27
    +314.51 (+2.01%)
     

  • VOLATILITY

    14.96
    -0.41 (-2.67%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6836
    +0.0015 (+0.22%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT RESULTS

Chevron, Exxon under pressure as falling natural gas prices hit earnings

Why Axsome Therapeutics Climbed Today While the Market Fell

Eric Volkman, The Motley Fool
·2 min read
Why Axsome Therapeutics Climbed Today While the Market Fell

In a somewhat counterintuitive development, shares of Axsome Therapeutics (NASDAQ: AXSM) rose on Thursday even though the company pointed out several issues in the development of one of its drugs. Following the company's latest update on the affected program, one analyst reiterated his bullish outlook on the shares, and they rose by 5.5%. In a regulatory filing, Axsome said it provided an official response to the Food and Drug Administration (FDA) regarding the pending New Drug Application (NDA) its AXS-05 drug candidate.

Continue reading